Fermenta Biotech Limited Issues Newspaper Publication Notice to Equity Shareholders Under Regulation 47

2 min read     Updated on 07 May 2026, 09:12 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Fermenta Biotech Limited published a newspaper notice on May 7, 2026, under Regulation 47 of SEBI (LODR) Regulations, 2015, informing equity shareholders about the transfer of shares with unpaid or unclaimed dividends for seven or more consecutive years to the IEPF Demat Account. Shareholders were required to submit claims for unpaid dividends for financial years commencing from 2018-19 (final dividend) by Wednesday, July 15, 2020, to avoid the transfer. The notice was published in Business Standard (English) and Sakal (Marathi), Mumbai editions, and was signed by Company Secretary & Head – Legal, Varadvinayak Khambete.

powered bylight_fuzz_icon
39714154

*this image is generated using AI for illustrative purposes only.

Fermenta Biotech Limited filed a newspaper publication notice with BSE Limited on May 7, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published in Business Standard, Mumbai (English version) and Sakal, Mumbai (Marathi version), and was submitted by Company Secretary & Head – Legal, Varadvinayak Khambete, under reference number F.No.: 908.

Notice to Equity Shareholders Regarding IEPF Transfer

In accordance with Section 124(6) and other applicable provisions of the Companies Act, 2013, read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, Fermenta Biotech notified its equity shareholders of the impending transfer of shares to the Investor Education and Protection Fund (IEPF) Demat Account. As per the applicable rules, all shares in respect of which dividend has remained unpaid or unclaimed for seven consecutive years or more are required to be transferred to the IEPF Demat Account.

Key Details of the Notice

The following table summarises the key parameters of the notice issued by Fermenta Biotech:

Parameter: Details
Publication Date: May 7, 2026
Newspapers Published In: Business Standard, Mumbai (English); Sakal, Mumbai (Marathi)
Regulatory Reference: Regulation 47, SEBI (LODR) Regulations, 2015
Applicable Law: Section 124(6), Companies Act, 2013; IEPF Rules, 2016
Deadline for Shareholder Claims: Wednesday, July 15, 2020
Dividend Period for Claims: Financial years commencing from 2018-19 (final dividend)
Registrar & Transfer Agent: MUFG Intime India Pvt Ltd (previously Link Intime India Pvt Ltd)
R&T Agent Address: C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400 083
R&T Agent Contact: Tel: +918108116767; Email: rnt.helpdesk@linkintime.co.in
Signed By: Varadvinayak Khambete, Company Secretary & Head – Legal

Shareholder Action Required

Fermenta Biotech communicated individually to concerned shareholders at their latest available addresses, informing them of the requirement to claim unpaid dividends. The company also uploaded details of such shareholders, along with equity shares due for transfer, on its website at www.fermentabiotech.com .

Shareholders were advised to make an application to the company and/or its Registrar and Transfer Agents by Wednesday, July 15, 2020, with a request for claiming unpaid dividends for financial years commencing from 2018-19 (final dividend). Failure to respond by this deadline would result in the company proceeding to transfer the respective shares to the IEPF Demat Account without further notice.

Mode of Transfer

The notice outlined two modes of share transfer to the IEPF Demat Account, depending on how the shares are held:

  • Equity shares held in physical form: Duplicate share certificates or letters of confirmation will be issued, and the concerned depository will convert these into dematerialised form before transferring to the IEPF Demat Account. Original share certificates will stand automatically cancelled and deemed non-negotiable.
  • Equity shares held in dematerialisation mode: Shares will be transferred directly to the dematerialised account of the IEPF Demat Account.

KYC Compliance Requirement

Fermenta Biotech also noted that as per SEBI Circular dated March 16, 2023 and other relevant circulars, outstanding payments in respect of equity shares will be credited directly to the bank accounts of shareholders holding equity shares in physical form only if the folio is KYC compliant. Both the dividend and equity shares transferred to IEPF/IEPF Demat Account, including all benefits accruing on such equity shares, can be claimed by the concerned equity shareholders from the IEPF Authority as per the procedure prescribed in the applicable rules.

Historical Stock Returns for Fermenta Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+0.96%+4.00%-3.30%-4.41%-4.41%-4.41%

How many shareholders and what total value of equity shares is Fermenta Biotech expected to transfer to the IEPF Demat Account if unclaimed dividends remain unaddressed?

How might the mandatory IEPF transfer of shares impact Fermenta Biotech's shareholder composition and future voting dynamics at general meetings?

What steps is Fermenta Biotech likely to take to improve shareholder KYC compliance following SEBI's March 2023 circular, and could non-compliance lead to regulatory scrutiny?

Fermenta Biotech Limited Submits SEBI Compliance Certificate for Q4 FY26

1 min read     Updated on 15 Apr 2026, 06:37 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Fermenta Biotech Limited filed its mandatory SEBI compliance certificate for Q4 FY26, confirming proper processing of dematerialization activities. The certificate, supported by registrar MUFG Intime India Pvt. Ltd., confirms all securities were processed within prescribed timelines with no rematerialization requests received during the quarter.

powered bylight_fuzz_icon
37804045

*this image is generated using AI for illustrative purposes only.

Fermenta Biotech Limited has submitted its quarterly compliance certificate to BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing, dated April 15, 2026, confirms the company's adherence to regulatory requirements for dematerialization processes.

Regulatory Compliance Certificate

The certificate confirms that during the quarter ended March 31, 2026, all securities received for dematerialization were processed in accordance with regulatory guidelines. The company has certified two key compliance aspects:

Compliance Parameter: Status
Securities Listing: All dematerialized securities listed on same exchanges as earlier securities
Certificate Processing: All certificates mutilated and cancelled after verification
Register Updates: Depository names substituted in register of members

Registrar Confirmation

MUFG Intime India Pvt. Ltd., formerly known as Link Intime India Pvt. Ltd., serving as the company's Registrar and Transfer Agent, provided supporting confirmation dated April 6, 2026. The registrar confirmed that all securities received from depository participants during the quarter were properly processed within prescribed timelines.

Key highlights from the registrar's confirmation include:

  • All dematerialization requests were confirmed or rejected to depositories as required
  • Security certificates were mutilated and cancelled after due verification
  • Depositories' names were substituted in the register of members within prescribed timelines
  • No rematerialization requests were received during the quarter

Corporate Details

Parameter: Details
Company: Fermenta Biotech Limited
CIN: L99999MH1951PLC008485
BSE Code: 506414
Registered Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400610
Company Secretary: Varadvinayak Khambete (Membership No. A33861)

The certificate was signed by Company Secretary and Head – Legal Varadvinayak Khambete, confirming the company's commitment to maintaining regulatory compliance in its securities operations.

Historical Stock Returns for Fermenta Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+0.96%+4.00%-3.30%-4.41%-4.41%-4.41%

Will Fermenta Biotech's consistent regulatory compliance help attract more institutional investors in the upcoming quarters?

How might the absence of rematerialization requests during Q1 2026 impact the company's digital transformation strategy?

Could MUFG Intime India's rebranding from Link Intime signal enhanced services that benefit Fermenta Biotech's shareholder management?

More News on Fermenta Biotech

1 Year Returns:-4.41%